(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 76.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Immunome's revenue in 2025 is $12,589,000.On average, 4 Wall Street analysts forecast IMNM's revenue for 2025 to be $604,527,581, with the lowest IMNM revenue forecast at $600,610,555, and the highest IMNM revenue forecast at $609,315,056. On average, 3 Wall Street analysts forecast IMNM's revenue for 2026 to be $2,198,756,902, with the lowest IMNM revenue forecast at $564,051,652, and the highest IMNM revenue forecast at $3,716,821,842.
In 2027, IMNM is forecast to generate $6,533,250,120 in revenue, with the lowest revenue forecast at $4,352,250,400 and the highest revenue forecast at $7,686,074,206.